Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | CCR8 | P51685 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 4/20 | 0.34 |
| ▸ | NOS2 | P35228 | 4/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 5/20 | 0.33 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.32 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
| ▸ | HTR3A | P46098 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30901326 | 1.00 | CCR1 (0.35) | CCR1CCR5CCR8NOS3NOS2 | |
| SCHEMBL22315284 | 0.81 | CCR1 (0.37) | CCR1CCR5CCR8NOS3NOS2 | |
| SCHEMBL29427142 | 0.78 | NOTUM (0.42) | NOS3NOS2NOTUMCYP1A2CYP2C9 | |
| SCHEMBL17002575 | 0.78 | CCR1 (0.38) | CCR1CCR5CCR8NOS3NOS2 | |
| SCHEMBL739829 | 0.78 | NOTUM (0.42) | NOS3NOS2NOTUMCYP1A2CYP2C9 | |
| Ammonia Solution, Strong SCHEMBL28037175 | 0.77 | CCR1 (0.37) | CCR1CCR5CCR8NOS3NOS2 | |
| SCHEMBL10387512 | 0.77 | PIK3CD (0.35) | NOS3NOS2NOTUMCYP1A2CYP2C9 | |
| SCHEMBL18328550 | 0.77 | TRPV4 (0.34) | NOS3NOS2NOTUMCYP1A2CYP2C9 | |
| SCHEMBL1034691 | 0.75 | NOS3 (0.39) | NOS3NOS2NOTUMCYP1A2CYP2C9 | |
| SCHEMBL11188610 | 0.75 | CCR1 (0.35) | CCR1CCR5CCR8NOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125364-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12338256-B2 | Aza-tetracyclic oxazepine compounds and uses thereof | GENENTECH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| EP-4526309-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | Genentech, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| EP-3873900-B1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | GILEAD SCIENCES INC (US) | 2025-01-08 | — | — | EP | disclosed |
| US-20240368186-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2024-11-07 | — | — | US | disclosed |
| EP-3873605-B1 | COMPOUNDS FOR INHIBITION OF ALPHA4BETA7 INTEGRIN | GILEAD SCIENCES INC (US) | 2024-10-23 | — | — | EP | disclosed |
| US-20240317713-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2024-09-26 | — | — | US | disclosed |
| US-11964961-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2024-04-23 | — | — | US | disclosed |
| CN-112969504-B | Compounds for inhibiting alpha 4 beta 7 integrin | 吉利德科学公司 | 2024-04-09 | — | — | CN | disclosed |
| US-9822097-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20170057947-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2017-03-02 | — | — | US | disclosed |
| US-9527831-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2016-12-27 | — | — | US | disclosed |
| EP-3013813-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | Pfizer Inc. (US) | 2016-05-04 | — | — | EP | disclosed |
| US-9139561-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9107923-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-20150196561-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2015-07-16 | — | — | US | disclosed |
| US-20150175573-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150005313-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2015-01-01 | — | — | US | disclosed |
| WO-2014207601-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2014-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125364-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | HTR6, HTR3C, OPRD1 | CCR1 743/4885CCR5 154/4885CCR8 1459/4885 |
| US-12338256-B2 | Aza-tetracyclic oxazepine compounds and uses thereof | AZI2, TET3, OXA1L | CCR1 3520/4885CCR5 2348/4885CCR8 3312/4885 |
| US-20150196561-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | SNCA, DRD1, DRD2 | CCR1 3762/4885CCR5 1855/4885CCR8 4714/4885 |
| US-11964961-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | DRD2, DRD1, HTR1D | CCR1 2498/4885CCR5 448/4885CCR8 3448/4885 |
| US-20240317713-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | DRD2, DRD1, HTR1D | CCR1 2498/4885CCR5 448/4885CCR8 3448/4885 |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | KRAS, NRAS, HRAS | CCR1 1296/4885CCR5 2108/4885CCR8 3673/4885 |
| US-20150005313-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | SNCA, DRD1, DRD2 | CCR1 3762/4885CCR5 1855/4885CCR8 4714/4885 |
| US-20150175573-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | DRD2, DRD1, HTR1D | CCR1 2498/4885CCR5 448/4885CCR8 3448/4885 |
| US-20240368186-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | AZI2, TET3, OXA1L | CCR1 3520/4885CCR5 2348/4885CCR8 3312/4885 |
| US-20170057947-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | DRD2, HTR1D, DRD1 | CCR1 2875/4885CCR5 593/4885CCR8 3778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.